文献速递乳腺癌

AURORA研究:乳腺癌原发灶与配对转移灶的基因组与转录组分析

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
PubMed 文献 · Cancer Discov · 2021-06-28

AURORA计划对381例转移性乳腺癌患者的原发灶与早期转移灶配对样本进行多组学分析,包括252对靶向基因测序、152对RNA测序和67对SNP阵列。发现GATA1和MEN1体细胞突变的驱动作用,转移灶富集ESR1、PTEN、CDH1、PIK3CA和RB1突变及MDM4、MYC扩增和ARID1A缺失;36%病例发生内在亚型转换,51%患者检测到ESCAT I/II级变异但仅7%接受匹配治疗。

要点

  • 转移灶富集ESR1、PTEN、CDH1、PIK3CA和RB1突变及MDM4、MYC扩增和ARID1A缺失。
  • 36%病例发生内在亚型转换,Luminal A/B向HER2富集转换与TP53和/或PIK3CA突变相关。
  • 51%患者检测到ESCAT I/II级变异,但仅7%接受匹配治疗。

核心结论

  • AURORA项目通过配对原发灶与转移灶的多组学分析,识别了转移灶富集的基因组变异和预后生物标志物。
  • 51%患者检测到ESCAT I/II级变异,但仅7%接受匹配治疗。
  • 将多组学分析整合到临床实践可能影响转移性乳腺癌的治疗策略。

研究设计与样本

  • AURORA为乳腺癌国际组(BIG)分子筛查计划,对配对原发灶和早期转移灶进行多组学分析。
  • 共纳入381例患者,其中252对样本行靶向基因测序,152对行RNA测序,67对行单核苷酸多态性阵列分析。

主要发现

  • 发现GATA1和MEN1体细胞突变具有驱动作用。
  • 转移灶富集ESR1、PTEN、CDH1、PIK3CA和RB1突变,MDM4和MYC扩增,以及ARID1A缺失。
  • 驱动基因如ERBB2和RB1中观察到克隆性增加。
  • 36%病例发生内在亚型转换,Luminal A/B向HER2富集转换与TP53和/或PIK3CA突变相关。
  • 转移灶免疫评分较低且免疫许可细胞增多;高肿瘤突变负荷与HR+/HER2-癌症较短复发时间相关。

关键数值与推荐

  • 51%患者检测到ESCAT I/II级变异,7%患者接受匹配治疗。
  • 36%病例发生内在亚型转换。
  • 高肿瘤突变负荷与HR+/HER2-癌症较短复发时间相关。

临床怎么用

  • 对转移性乳腺癌患者进行配对原发灶与转移灶的多组学分析有助于识别可靶向变异和预后标志物。
  • ESCAT I/II级变异检出率较高但匹配治疗使用率低,提示需加强分子检测结果向治疗决策的转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for GATA1 and MEN1 somatic mutations. Metastases were enriched in ESR1, PTEN, CDH1, PIK3CA, and RB1 mutations; MDM4 and MYC amplifications; and ARID1A deletions. An increase in clonality was observed in driver genes such as ERBB2 and RB1. Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-enriched switching was associated with TP53 and/or PIK3CA mutations. Metastases had lower immune score and increased immune-permissive cells. High tumor mutational burden correlated to shorter time to relapse in HR+/HER2- cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could affect treatment strategies in MBC. SIGNIFICANCE: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic samples from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients.This article is highlighted in the In This Issue feature, p. 2659.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Aftimos P, Oliveira M, Irrthum A, et al. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. Cancer Discov. 2021. PMID: 34183353. doi:10.1158/2159-8290.CD-20-1647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。